Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …

Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline
treatment R-CHOP, but 30–40% of patients are still unresponsive or relapse thereafter. In …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

New treatments are needed for B-cell malignancies persisting after allogeneic
hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of …

Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies
are not cured by current standard therapies. Chimeric antigen receptors (CARs) are fusion …

Allogeneic hematopoietic cell transplantation (alloHCT) can potentially salvage large B-cell
lymphoma (LBCL) patients experiencing treatment failure after chimeric antigen receptor T …

1Department of Haematology, Queen Elizabeth Hospital, Birmingham, 2Department of
Clinical Oncology, Christie Hospital, Manchester, 3PET Imaging Centre, King's College …

Diffuse large B cell lymphoma represents the most common type of non-Hodgkin lymphoma.
Although the curability rate is high, around 40% of patients will relapse or exhibit refractory …

Multiple natural killer (NK) cell-based anticancer therapies are currently under development.
Here, we compare the efficiency of genetically modified NK-92 cells expressing chimeric …